Sana Biotechnology CFO Nathan Hardy resigns; CEO Harr named acting PFO, Susan Wyrick acting CFO

Sana Biotechnology, Inc.

CFO Nathan Hardy resigned effective Oct 4, 2024; acting appointments made same day.
CEO Steven D. Harr appointed acting Principal Financial Officer; no compensation change.
Susan Wyrick appointed Acting CFO, Treasurer, and PAO; receives $5k/month extra, $25k bonus, 20,000 RSUs.
Wyrick previously SVP Finance; former VP Controller at Juno Therapeutics prior to Celgene acquisition.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nathan Hardy

Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer

SANA · Sana Biotechnology, Inc.

Effective: 2024-10-04
Successor: Susan Wyrick
Filed: October 8, 2024, 7:59 PM ET

Nathan Hardy’s resignation as Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer (“PFO”), and Principal Accounting Officer (“PAO”)

Appointed (interim)

Susan Wyrick

Acting Chief Financial Officer, Treasurer, and Principal Accounting Officer

SANA · Sana Biotechnology, Inc.

Effective: 2024-10-04
Filed: October 8, 2024, 7:59 PM ET

Susan Wyrick, the Company’s Senior Vice President, Finance and Accounting, was appointed to serve as Acting Chief Financial Officer, Treasurer, and PAO

Appointed (interim)

Steven D. Harr

acting Principal Financial Officer

SANA · Sana Biotechnology, Inc.

Effective: 2024-10-04
Filed: October 8, 2024, 7:59 PM ET

Steven D. Harr, M.D., the Company’s President and Chief Executive Officer, was appointed to serve as acting PFO in addition to his role as President and Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nathan Hardy resigned as Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer at Sana Biotechnology, Inc..

Action: resigned
Role: Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer

Exact text from the filing

Nathan Hardy’s resignation as Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer (“PFO”), and Principal Accounting Officer (“PAO”)

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Susan Wyrick was appointed as Acting Chief Financial Officer, Treasurer, and Principal Accounting Officer at Sana Biotechnology, Inc..

Action: appointed
Role: Acting Chief Financial Officer, Treasurer, and Principal Accounting Officer

Exact text from the filing

Susan Wyrick, the Company’s Senior Vice President, Finance and Accounting, was appointed to serve as Acting Chief Financial Officer, Treasurer, and PAO

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven D. Harr was appointed as acting Principal Financial Officer at Sana Biotechnology, Inc..

Action: appointed
Role: acting Principal Financial Officer

Exact text from the filing

Steven D. Harr, M.D., the Company’s President and Chief Executive Officer, was appointed to serve as acting PFO in addition to his role as President and Chief Executive Officer.

View on SEC.gov

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-113524

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.